Cerebral metabolic patterns in chronic and recent-onset schizophrenia.
This article compares the effects of short- and long-term treatment with haloperidol in schizophrenic patients, with the aim of identifying brain metabolic activity patterns common to acute and chronic patients in spite of their different treatment and illness duration. [18F]fluoro-deoxy-glucose (FDG)-positron emission tomography (PET) studies in the resting condition were performed on 18 healthy controls and two groups of schizophrenic patients: recent onset (RO, n=17) minimally treated with haloperidol, and chronic long-term treated patients (LT, n=34). PET scans were analyzed using statistical parametric mapping (SPM'99) and the P-value threshold to assess differences between groups was validated by bootstrapping techniques. Our results show a distinctive pattern of decreased activation of the visual cortex in RO and LT patients, when compared to healthy controls. Insular hypometabolism and a certain degree of hypofrontality were observed in the LT group when compared to RO patients. The main effect of the long-term administration of haloperidol seems to be an increase of cerebellar, basal ganglia and motor area metabolism.
Desco
Manuel
M
Department of Experimental Medicine, Hospital General Universitario Gregorio Marañón, Dr. Esquerdo 46, E-28007 Madrid, Spain. desco@mce.hggm.es
Gispert
Juan D
JD
Reig
Santiago
S
Sanz
Javier
J
Pascau
Javier
J
Sarramea
Fernando
F
Benito
Carlos
C
Santos
Andrés
A
Palomo
Tomás
T
Molina
Vicente
V
D000208:Acute Disease; D000328:Adult; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000187:drug effects; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects*; D001931:Brain Mapping; D002531:Cerebellum / Q000000981:diagnostic imaging / Q000187:drug effects; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000187:drug effects; D002908:Chronic Disease; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000000981:diagnostic imaging / Q000187:drug effects; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009044:Motor Cortex / Q000000981:diagnostic imaging / Q000187:drug effects; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D014055:Tomography, Emission-Computed; D014793:Visual Cortex / Q000000981:diagnostic imaging / Q000187:drug effects
D019788:Fluorodeoxyglucose F18; D006220:Haloperidol